Hanson Pharmaceuticals announced that in 2011, the company plans to purchase 173 acres of development land to expand the production line for basic drug products. Due to poor land vacancy, the contract was re-signed in 2022, and no substantial construction has been carried out so far. Due to environmental changes in the pharmaceutical industry and land listing, etc., after careful verification, the company decided not to proceed with the project and has negotiated with the relevant parties to terminate it. This matter does not involve related transactions or major asset restructuring, and will not have a significant adverse impact on the company's current production, operation and financial situation.

Hanson Pharmaceuticals announced that in 2011, the company plans to purchase 173 acres of development land to expand the production line for basic drug products. Due to poor land vacancy, the contract was re-signed in 2022, and no substantial construction has been carried out so far. Due to environmental changes in the pharmaceutical industry and land listing, etc., after careful verification, the company decided not to proceed with the project and has negotiated with the relevant parties to terminate it. This matter does not involve related transactions or major asset restructuring, and will not have a significant adverse impact on the company's current production, operation and financial situation.